Enanta Hopes To Succeed In RSV With N-Protein Inhibition Approach
Executive Summary
Enanta's N-protein inhibitor EDP-938 hit a pair of endpoints in a Phase IIa challenge study, but real-world testing may be a higher hurdle. The company believes its therapeutic approach is more effective than fusion protein prophylactic approaches.
You may also be interested in...
Enanta Stumbles In Trying To Show Better FXR Agonist Profile In NASH
Enanta hoped its Phase II study would indicate a better efficacy and/or tolerability profile for EDP-305 compared to other FXR agonists for NASH, including Intercept’s OCA. Despite the inconclusive data, it plans a longer Phase IIb study.
Alios Buy Best Forgotten For Johnson & Johnson As RSV Failure Costs It Dear
Johnson & Johnson has written off a further $700m against the RSV asset that it obtained with its $1.75bn purchase of Alios.
Novavax Looks To Secondary Endpoints As Phase III RSV Vaccine Trial Fails
Novavax’s shares plunged 67% on news that its Phase III trial for RSV had failed, but are there signs of life for the product?